[On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002699:Chlorambucil / Q000627:therapeutic use; D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004351:Drug Resistance; D004357:Drug Synergism; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D003510:Cyclohexanes; D009607:Nitrosourea Compounds; D002699:Chlorambucil; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D002330:Carmustine; D011241:Prednisone
Zur Therapie ds Lymphogranuloms. CCNU (1-(2-Chloräthyl)-3-zyklohexyl-1-Nitrosourea) und BCNU (1,3-bis(2-Chloroäthyl)-1-Nitrosourea) sowie BCNU-Kombinationen beim Lymphogranulom Hodgkin, Stadium 3 und 4.